Lyra Therapeutics, Inc. is a biotechnology company founded in 2005, specializing in innovative drug and delivery solutions for ear, nose, and throat diseases. Using its proprietary XTreo technology platform, Lyra ensures precise and consistent medication delivery directly to affected tissues for extended periods with just one administration. Their initial product candidates, LYR-210 and LYR-220, offer up to six months of continuous drug therapy for the treatment of CRS through a brief, non-invasive, in-office procedure. These products utilize mometasone furoate, known for its well-documented efficacy and safety profile.
The latest milestone for Lyra Therapeutics is a $50.00M Post-IPO Equity investment, secured on 26 May 2023. The investment was led by Perceptive Advisors, Samsara BioCapital, Woodline Partners, Venrock Healthcare Capital Partners, Surveyor Capital, North Bridge Venture Partners & Growth Equity, Nantahala Capital Management, and Armistice Capital, showcasing strong support and confidence from a diverse group of investors.
